Details for New Drug Application (NDA): 217906
✉ Email this page to a colleague
The generic ingredient in EMBLAVEO is avibactam sodium; aztreonam. One supplier is listed for this compound. Additional details are available on the avibactam sodium; aztreonam profile page.
Summary for 217906
Tradename: | EMBLAVEO |
Applicant: | Abbvie |
Ingredient: | avibactam sodium; aztreonam |
Patents: | 7 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217906
Generic Entry Date for 217906*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 217906
Mechanism of Action | beta Lactamase Inhibitors |
Suppliers and Packaging for NDA: 217906
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
EMBLAVEO | avibactam sodium; aztreonam | POWDER;INTRAVENOUS | 217906 | NDA | AbbVie Inc. | 0074-3878 | 0074-3878-01 | 10 POWDER, FOR SOLUTION in 1 CARTON (0074-3878-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 0.5GM BASE/VIAL;1.5GM/VIAL | ||||
Approval Date: | Feb 7, 2025 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Try for Free | Patent Expiration: | Jan 7, 2026 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | TREATMENT OF COMPLICATED INTRA-ABDOMINAL BACTERIAL INFECTIONS IN ADULT PATIENTS | ||||||||
Patent: | ⤷ Try for Free | Patent Expiration: | Nov 12, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Try for Free | Patent Expiration: | Aug 12, 2031 | Product Flag? | Substance Flag? | Y | Delist Request? |
Complete Access Available with Subscription